BCTX BriaCell Therapeutics Corp
Price (delayed)
$3.61
Market cap
$13.39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.03
Enterprise value
$8.38M
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
Highlights
The EPS has surged by 62% since the previous quarter and by 58% year-on-year
The net income has increased by 30% QoQ and by 7% YoY
The company's equity has surged by 140% YoY but it fell by 13% QoQ
BriaCell Therapeutics's quick ratio has decreased by 40% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of BCTX
Market
Valuations
Earnings
Shares outstanding
3.71M
Market cap
$13.39M
Enterprise value
$8.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.3
Price to sales (P/S)
N/A
EV/EBIT
7.41
EV/EBITDA
6.65
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$27.32M
Net income
-$11.78M
EBIT
$1.13M
EBITDA
$1.26M
Free cash flow
-$22.45M
Per share
Balance sheet
Liquidity
EPS
-$5.03
EPS diluted
-$5.03
Free cash flow per share
-$8.32
Book value per share
$1.09
Revenue per share
$0
TBVPS
$3.4
Total assets
$9.36M
Total liabilities
$6.14M
Debt
$0
Equity
$3.23M
Working capital
$1.93M
Debt to equity
0
Current ratio
1.37
Quick ratio
0.96
Net debt/EBITDA
-3.98
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-147.9%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
27.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCTX stock price
How has the BriaCell Therapeutics stock price performed over time
Intraday
4.03%
1 week
-9.98%
1 month
-1.63%
1 year
-91.25%
YTD
-57.38%
QTD
-1.1%
Financial performance
How have BriaCell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$27.32M
Net income
-$11.78M
Gross margin
N/A
Net margin
N/A
The net income has increased by 30% QoQ and by 7% YoY
The company's operating income rose by 14% YoY and by 9% QoQ
Growth
What is BriaCell Therapeutics's growth rate over time
Valuation
What is BriaCell Therapeutics stock price valuation
P/E
N/A
P/B
3.3
P/S
N/A
EV/EBIT
7.41
EV/EBITDA
6.65
EV/Sales
N/A
The EPS has surged by 62% since the previous quarter and by 58% year-on-year
The company's equity has surged by 140% YoY but it fell by 13% QoQ
Efficiency
How efficient is BriaCell Therapeutics business performance
BCTX's ROA has dropped by 156% year-on-year but it is up by 23% since the previous quarter
Dividends
What is BCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCTX.
Financial health
How did BriaCell Therapeutics financials performed over time
The total assets is 53% greater than the total liabilities
The total liabilities has plunged by 70% YoY and by 8% from the previous quarter
BriaCell Therapeutics's current ratio has shrunk by 54% YoY and by 17% QoQ
The debt is 100% smaller than the equity
The company's equity has surged by 140% YoY but it fell by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.